Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry I do not have the Symphony numbers. But am hoping someone on here can get them and post as I was told there is a large discrepancy.
Does anyone on here have access to actual Symphony sales numbers? A friend of mine who does, compared the Symphony numbers to what is being reported by Bloomberg. They said there was no correlation between the two and said that the MNK numbers for Seroquel XR are much lower on Symphony... I am wondering if anyone else has access to Symphony data and can confirm this?
Amigo- I think that was me saying that I did not have any idea on what the VP of Commercial Operations does all day. I said that they have made one F****** deal since the PAR deal and he must just sit at his desk with his feet up on it waiting for the phone to ring...
Tilator- What else do you have going on regarding this issue?
Doog- Please elaborate on Biosphere.
Tilator- You sound like you are an expert on how to get Gluco to market. Have you offered your consulting services to IPCI in an attempt to help them do just that?
tilator- Question for you. If the competition on Metformin has been manufacturing it for years and also has low cost overseas production facilities aimed at high volume, low cost, low margin pharma products. How on earth will IPCI and their small manufacturing site- that was originally aimed at producing pharmaceuticals as part of product development- beat these guys on price. I believe therein lies the problem.
Well said Doog and Fabius.
tilator- Just an educated guess.
Samsa- You pointed out micro management at IPCI. I really think that is one of the big reasons everything moves so slow...
Tilator- You are wrong. MNK has roughly 4-5% of the generic Seroquel XR market.
Tilator- These are the only companies with XR approvals...
QUETIAPINE FUMARATE QUETIAPINE FUMARATE A090681 TABLET, EXTENDED RELEASE ORAL EQ 150MG BASE AB ACCORD HEALTHCARE INC
RX QUETIAPINE FUMARATE QUETIAPINE FUMARATE A202939 TABLET, EXTENDED RELEASE ORAL EQ 150MG BASE AB INTELLIPHARMACEUTICS CORP
RX QUETIAPINE FUMARATE QUETIAPINE FUMARATE A204203 TABLET, EXTENDED RELEASE ORAL EQ 150MG BASE AB LUPIN LTD
RX QUETIAPINE FUMARATE QUETIAPINE FUMARATE A090482 TABLET, EXTENDED RELEASE ORAL EQ 150MG BASE AB PAR PHARMACEUTICAL INC
RX QUETIAPINE FUMARATE QUETIAPINE FUMARATE A206260 TABLET, EXTENDED RELEASE ORAL EQ 150MG BASE AB PHARMADAX INC
RX QUETIAPINE FUMARATE QUETIAPINE FUMARATE A090681 TABLET, EXTENDED RELEASE ORAL EQ 200MG BASE AB ACCORD HEALTHCARE INC
tilator- Just stop... You are wrong. Look at his cut and paste. It does not say XR. There are only about 5 companies approved for Generic Seroquel XR.
Angelo- The giveaway is most of those companies listed DO NOT have a generic Seroquel XR approval so it has to be both.
Tilator- It has both. Go check for yourself. Most of those names on that list DO NOT have a generic Seroquel XR approval yet...
Fred- Those prescription numbers you posted also include the standard Seroquel prescription as well as the XR. The standard prescriptions still far exceed the XR ones.
Fred- Since the growth has stalled, I am thinking we don't see an uptick until MNK can get a chance to bid on some of the orders that were locked up prior to MNK getting the product released.
Q4 is going to be disappointing for sure. My rough guess now is we might see $2M total revenue absolute tops.
This changeover in the movie industry could be very disruptive. What I see is someone creating a business that will lower the cut for the theatre owners and people making the films. I don't see how they will get away with "eating someone else's lunch" while those people passively sit back and watch. Should be interesting.
A big problem I see is at times when they can fill the theatres easily at full price- premiers, weekends, holidays, etc. They are not going to like giving half the seats away at lower prices.
The reason I have not signed up for this service is I was able to get a Marcus Rewards card for free. On Tuesday nights all movies are $5 plus with the rewards program I get free popcorn as well. So I might go 1-2 times per month. Never more than 2... And I will get free popcorn too! And if I don't go at all, I pay nothing!
Fabius- This year should be very telling for IPCI's future. Either they deliver or they never will.
blue- You are probably right I should sell everything. I just think right now is not the right time to do that. I used to have faith that deals and approvals were coming. Now after years of pretty much nothing, I think more inactivity is coming. Right now I am looking for a better time to get out. Now if they actually showed some signs of life, I might change my tone.
Doog- I gotta wonder too if these CFOs keep leaving because they cannot talk sense into Odidi.
The only buying I could see doing at these levels is for a trade. Get in and get out before more bad news. It will be real hard to get past $2 just based on the price of the offering. The thing I have seen with IPCI in the past 4 years is everything moves extremely slow. That is except the mounting failures, bad news, IP collecting dust, worthless patents being issed, etc.
Oh and when the pumpers swear up and down it is going to $4. They will be unloading and shorting at $2.50...
Doog- I had my "moment of clarity" shortly after adcom. At that point, I reviewed what they had done since the initial Focalin approval... All I see now is a train wreck. If they don't start to find ways to get commercial returns in the coming year, very sadly I feel they never will.
Doog- I think if things don't change the writing is on the wall. Eventually he loses control of the company and I think everything will be sold off. The only thing that can change this train wreck is if they wake up and realize their technology is worth what the market is offering. Patents only expire when they are left on the shelf and if they do start licensing out the IP, there will be a lot of woulda, coulda, shoulda...
That's the whole scam. They pump and pump and pump... Claim to be buying, all the while selling( last time we saw this it around $1.05). Lure the suckers in and sell. Then promise news and phony PR. No news... People begin to get nervous. Then out comes the negativity and walk it down with wash trading. Then they say its going to drop another 10-20%. Stop losses kick in and traders sell. This when they buy...
Merger between IPCI and Cerecor? Come on... Boyd owns stock in many pharmaceutical companies and sits on the board of one. I don't see any relation between IPCI and Cerecor other than the same hedge fund owns a chunk of each. I can see the wheels are already spinning at how to come up with the next phony PR rumor.
Fred- Is there any chance these numbers are way off? And the sales are lower than shown? These are Bloomberg? Do you have access Symphony sales nymbers? Or are these the same?
Interview of Dr. Odidi last February:
https://www.midasletter.com/2017/02/intellipharmaceutics-ceo-dr-issa-odidi-preventing-overdose-death-oxycodone-fentanyl/#
Lots of talk about PODRAS and Regabatin... But they have done absolutely nothing with either in the 8 months since this interview... So much potential but such little focus and effort making these technologies real...
Here is a great article about Dr. Odidi and his accomplishments:
http://www.pharmanewsonline.com/prof-isa-odidi-the-pharmacist-ahead-of-his-time/
Please take note that he was at Biovail 1995-1999. In those few years Biovail supposedly transformed to a commercially viable company. Now with that in mind, consider how many years IPCI has been floundering with its pipeline and cannot even get close to cash flow neutral let alone positive.
Tek- At some point the dilution will catch up with him and he is not going to like what that reality holds. Like you said- a man can be stubborn- and that is what I am seeing. I know there is a lot of complaining to management right now. Lets hope Odidi is listening and realizes the company has not delivered. If he does not, he will eventually lose control and all pieces will be sold off individually. That is really all I can see happening if they do not make the needed adjustments.
Tek- But they have a VP of Commercial Operations... If that guy is the problem then get rid of him. That guy supposedly has the right connections... But I don't think he is the problem. I think Odidi is a huge roadblock in getting deals and licensing done.
Doog- I suspect Penna left because of Odidi and his unwillingless to listen. I suspect Patient took the job because it is a job with pay. Like I said the only thing Odidi moves fast at is filling the vacant CFO position... Why? I tell you why... He needs access to capital markets as an ATM for his worthless patents and research.
Doog- Yes things could turn around. But IPCI's track record is continuous delays, excuses, failures and progress at a snails pace. They have been talking new approvals and CFP status since 2013... I now see the absurdity in this all. They just DO NOT deliver. If you look at their website, it is nearly the same BS as was on it in 2013. They talk about developing new chemical entities for other companies... Really- when have they ever done this? They talk about licensing their proprietary controlled release delivery system to others... Really- when have they ever done this? They have had that crap on their website since when I came on board in 2013. Also Regabatin has not made one iota of progress since 2013 either- it has to be dead. They just plain don't deliver and I guess the next year will be more disappointments as well. It appears that they are not getting Pristiq or Lamictal approvals anytime soon. Once again there ANDA pipeline delayed again. How many times have we heard this? My guess is deficient applications that were kicked back. For once I would like the company to come out and deliver some good news...
doog- I really get the impression he is an absolute micro manager that does not let has staff have any leeway. That is the absolute worst trait in a CEO. A CEO needs to be able to delegate authority and have trust in his staff. I get the impression he fails terribly in this regard.
doog- Answer is simple... He thinks he is this great scientist and thinks all his ideas are great... So his focus is on doing the research and patenting every one... And he is doing this with shareholders money... So at some point these need to be used to recoup the money we have given him to do this research and obtain these patents. We did not give him this money to put a feather in his cap and say I am the smartest guy in the room. If he wants this go work in academia- where no one is accountable for delivering anything. We did it to gain a return on our investment. And he is absolutely oblivious to this fact!
doog- I am starting to get the impression that Dr. Odidi is the following things:
1. Micro manager that will not let others do their jobs. He has to be involved in every decision, every negotiation, every modification to factory floor, everything. That is unfortunate, since he needs to be working on moving the pipeline forward and getting the relevant approvals. I think he needs to learn to let his employees do their jobs and have confidence in them. He has a VP of Commercial Operations. He should let that person handle the deals, etc. He should stay out of it.
2. Thinks his ideas and science are much more revolutionary than they are. They are not making a dime on a single patent. There are no licensing payments, etc. I think that tells you that he gets an idea, patents it and then it just sits collecting dust.
3. Out of touch with reality. In particular, I think he thinks his IP is worth far more than what the industry is willing to pay for it. Thus, he blows every deal they have in the works.
4. Impossible to work with and has a poor industry reputation.
Now these of course are only my opinions. But I have a feeling that some of this is spot on. I think Regabatin is an example of an idea that he waited to long on. The window for this product may indeed be gone. The one saving grace is Pfizer did not get approval for Fibromyalgia.
And the Reagabatin patent is just another useless piece of paper that Odidi cannot or will not monetize!
doog- What I have been saying the last couple days is IPCI and the Odidi's have many, many patents... But how many of those patents are licensed or earning them any money? EXACTLY 0. It is now my opinion that Odidi should work for a University and do his research and file his patents where no one expects a return. Odidi has shown that he cannot monetize any of his technology. Everyone needs to remember patents expire and IPCI's portfolio of IP is sitting on the shelf collecting dust JUST LIKE TWO OF THEIR APPROVALS! Odidi has failed miserably with IPCI and their IP protection will be expired and usable by the public for free before Odidi ever wakes up...
Numbers- Exactly... That is why I have been saying Regabatin is a dead product. The elephant in the room got an approval before IPCI HAS EVEN BEGUN PH3 TESTS... And they still try to mislead shareholders that Regabatin is a viable product... If it really was, it would have been partnered years ago.
Doog and TREND- IPCI is estimating the Rexista HAL studies to cost between $1.5-2M and will begin before mid December.